English

MARRONE BIO INNOVATIONS INC

EDGAR

MBII Quarterly report (10-Q) · filed 2022-05-13

138 filing records in this dataset, filed from 2013-07-01 to 2022-05-13. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

11.1 million USD

2022 Q1 · USD

Exact inputs and evidence

Revenue: 11097000 USD Source

Operating margin

-63.28%

2022 Q1 · %

Exact inputs and evidence

Operating Income: -7022000 USD Source
Revenue: 11097000 USD Source

Operating cash flow

-8.4 million USD

2022 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -8396000 USD Source

Free cash flow

-8.59 million USD

2022 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -8396000 USD Source
Capital Expenditure: 198000 USD Source

Cash and cash equivalents: 9.36 million USD 2022-03-31 Source
Exact value

9362000 USD
Long-term debt including current maturities: 32.1 million USD 2022-03-31 Source
Exact value

32052000 USD
Shares outstanding: 182 million shares 2022-03-31 Source
Exact value

182275000 shares

Reported share-count change

3.99% · 7 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

175274000 shares · 2021-03-31· Source
182275000 shares · 2022-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

44.4 million USD

2021-04-01 – 2022-03-31

Exact inputs and evidence

Revenue: 12598000 USD · 2021-04-01 – 2021-06-30 Source
Revenue: 9856000 USD · 2021-07-01 – 2021-09-30 Source
Revenue: 44310000 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 33492000 USD · 2021-01-01 – 2021-09-30 Source
Revenue: 11097000 USD · 2022-01-01 – 2022-03-31 Source

Net income

-20.9 million USD

2021-04-01 – 2022-03-31

Exact inputs and evidence

Net income: -3035000 USD · 2021-04-01 – 2021-06-30 Source
Net income: -4945000 USD · 2021-07-01 – 2021-09-30 Source
Net income: -16554000 USD · 2021-01-01 – 2021-12-31 Source
Net income: -11241000 USD · 2021-01-01 – 2021-09-30 Source
Net income: -7596000 USD · 2022-01-01 – 2022-03-31 Source

Operating cash flow

-13.3 million USD

2021-04-01 – 2022-03-31

Exact inputs and evidence

Operating cash flow: -6263000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -5017000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -6571000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -6263000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -9961000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -6571000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -8396000 USD · 2022-01-01 – 2022-03-31 Source

Capital expenditure

1.17 million USD

2021-04-01 – 2022-03-31

Exact inputs and evidence

Capital expenditure: 544000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 119000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 905000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 544000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 1093000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 905000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 198000 USD · 2022-01-01 – 2022-03-31 Source

Free cash flow

-14.5 million USD

2021-04-01 – 2022-03-31

Exact inputs and evidence

Operating cash flow: -6263000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -5017000 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: -6571000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -6263000 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: -9961000 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: -6571000 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: -8396000 USD · 2022-01-01 – 2022-03-31 Source
Capital expenditure: 544000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 119000 USD · 2021-01-01 – 2021-03-31 Source
Capital expenditure: 905000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 544000 USD · 2021-01-01 – 2021-06-30 Source
Capital expenditure: 1093000 USD · 2021-01-01 – 2021-12-31 Source
Capital expenditure: 905000 USD · 2021-01-01 – 2021-09-30 Source
Capital expenditure: 198000 USD · 2022-01-01 – 2022-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2022-05-13.

Financial data available through: 2021-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2021-12-31
Operating income: 11 of 11 periods available· newest 2021-12-31
Net income: 10 of 11 periods available· newest 2021-12-31
Operating cash flow: 11 of 11 periods available· newest 2021-12-31
Capital expenditure: 11 of 11 periods available· newest 2021-12-31
Total assets: 10 of 11 periods available· newest 2021-12-31
Total liabilities: 10 of 11 periods available· newest 2021-12-31
Current assets: 10 of 11 periods available· newest 2021-12-31
Current liabilities: 10 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2021-12-31
Long-term debt including current maturities: 10 of 11 periods available· newest 2021-12-31
Shares outstanding: 10 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+15.5%

Prior period

USD 38.37 million

2020-01-01 – 2020-12-31
Current period

USD 44.31 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

44310000 − 38374000 = 5936000 USD

38374000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
44310000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · MARRONE BIO INNOVATIONS INC · 2021-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Year-over-year change in Revenue: 5936000 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 44310000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#428781 Filing: 000149315222012535 Input fundies:Revenue: 38374000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#429626 Filing: 000149315222012535
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 3.61 million

Prior period

−USD 20.17 million

2020-01-01 – 2020-12-31
Current period

−USD 16.55 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-16554000 − -20168000 = 3614000 USD

-20168000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-16554000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · MARRONE BIO INNOVATIONS INC · 2021-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Year-over-year change in Net income: 3614000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -16554000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#584350 Filing: 000149315222012535 Input fundies:NetIncome: -20168000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#585202 Filing: 000149315222012535
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 6 million

Prior period

−USD 15.96 million

2020-01-01 – 2020-12-31
Current period

−USD 9.96 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

-9961000 − -15959000 = 5998000 USD

-15959000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-9961000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · MARRONE BIO INNOVATIONS INC · 2021-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Year-over-year change in Operating cash flow: 5998000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -9961000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#622851 Filing: 000149315222012535 Input fundies:OperatingCashFlow: -15959000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#623805 Filing: 000149315222012535
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+95.5%

Prior period

USD 559,000

2020-01-01 – 2020-12-31
Current period

USD 1.09 million

2021-01-01 – 2021-12-31

Exact inputs and evidence

1093000 − 559000 = 534000 USD

559000 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
1093000 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · MARRONE BIO INNOVATIONS INC · 2021-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Year-over-year change in Capital expenditure: 534000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1093000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#628953 Filing: 000149315222012535 Input fundies:CapitalExpenditure: 559000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#629784 Filing: 000149315222012535
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 44.31 million 100% of revenue
Cost of revenue USD 17.06 million 39% of revenue
Operating expenses USD 42.65 million 96% of revenue
Operating income −USD 15.4 million −35% of revenue
Tax, interest and other Derived USD 1.15 million 2.6% of revenue
Net income −USD 16.55 million −37% of revenue

Cash

Operating cash flow −USD 9.96 million −22% of revenue
Capital expenditure USD 1.09 million 2.5% of revenue
Free cash flow Derived −USD 11.05 million −25% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2012 Operating loss: operating costs were 434% of revenue.
2013 Operating loss: operating costs were 476% of revenue.
2014 Operating loss: operating costs were 631% of revenue.
2015 Operating loss: operating costs were 503% of revenue.
2016 Operating loss: operating costs were 268% of revenue.
2017 Operating loss: operating costs were 227% of revenue.
2018 Operating loss: operating costs were 192% of revenue.
2019 Operating loss: operating costs were 195% of revenue.
2020 Operating loss: operating costs were 145% of revenue.
2021 Operating loss: operating costs were 135% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2012 2012-01-01 – 2012-12-31	7140000	30978000 Derived	-23838000	14956000 Derived	-38794000	-25182000 Derived	Source 2012-01-01 – 2012-12-31: 7140000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: -23838000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -38794000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: -22425000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 2757000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	8446000	40165000 Derived	-31719000	-477000 Derived	-31242000	-38030000 Derived	Source 2013-01-01 – 2013-12-31: 8446000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: -31719000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -31242000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: -34064000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 3966000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	9136000	57669000 Derived	-48533000	3126000 Derived	-51659000	-48937000 Derived	Source 2014-01-01 – 2014-12-31: 9136000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: -48533000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -51659000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: -35935000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 13002000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	9801000	49258000 Derived	-39457000	4271000 Derived	-43728000	-37827000 Derived	Source 2015-01-01 – 2015-12-31: 9801000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: -39457000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -43728000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: -36174000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 1653000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	14042000	37702000 Derived	-23660000	7411000 Derived	-31071000	-24516000 Derived	Source 2016-01-01 – 2016-12-31: 14042000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -23660000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -31071000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: -24307000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 209000 USD Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	18167000	41162000 Derived	-22995000	7930000 Derived	-30925000	-21905000 Derived	Source 2017-01-01 – 2017-12-31: 18167000 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -22995000 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -30925000 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -21056000 USD Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 849000 USD Inspect Capital Expenditure Open source
2018 2018-01-01 – 2018-12-31	21220000	40724000 Derived	-19504000	709000 Derived	-20213000	-20005000 Derived	Source 2018-01-01 – 2018-12-31: 21220000 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -19504000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -20213000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -19425000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 580000 USD Inspect Capital Expenditure Open source
2019 2019-01-01 – 2019-12-31	29373000	57358000 Derived	-27985000	9190000 Derived	-37175000	-21635000 Derived	Source 2019-01-01 – 2019-12-31: 29373000 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -27985000 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -37175000 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: -21339000 USD Inspect Operating Cash Flow Open source 2019-01-01 – 2019-12-31: 296000 USD Inspect Capital Expenditure Open source
2020 2020-01-01 – 2020-12-31	38374000	55569000 Derived	-17195000	2973000 Derived	-20168000	-16518000 Derived	Source 2020-01-01 – 2020-12-31: 38374000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -17195000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -20168000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: -15959000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 559000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	44310000	59714000 Derived	-15404000	1150000 Derived	-16554000	-11054000 Derived	Source 2021-01-01 – 2021-12-31: 44310000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -15404000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -16554000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -9961000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1093000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 44.3M 2021

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Revenue	7140000	Revenue: 7140000 Open source
20132013-12-31	Revenue	8446000	Revenue: 8446000 Open source
20142014-12-31	Revenue	9136000	Revenue: 9136000 Open source
20152015-12-31	Revenue	9801000	Revenue: 9801000 Open source
20162016-12-31	Revenue	14042000	Revenue: 14042000 Open source
20172017-12-31	Revenue	18167000	Revenue: 18167000 Open source
20182018-12-31	Revenue	21220000	Revenue: 21220000 Open source
20192019-12-31	Revenue	29373000	Revenue: 29373000 Open source
20202020-12-31	Revenue	38374000	Revenue: 38374000 Open source
20212021-12-31	Revenue	44310000	Revenue: 44310000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

15.5% 2021

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Year over year	36%	Revenue: 7140000 Open source Revenue: 5251000 Open source
20132013-12-31	Year over year	18.3%	Revenue: 8446000 Open source Revenue: 7140000 Open source
20142014-12-31	Year over year	8.2%	Revenue: 9136000 Open source Revenue: 8446000 Open source
20152015-12-31	Year over year	7.3%	Revenue: 9801000 Open source Revenue: 9136000 Open source
20162016-12-31	Year over year	43.3%	Revenue: 14042000 Open source Revenue: 9801000 Open source
20172017-12-31	Year over year	29.4%	Revenue: 18167000 Open source Revenue: 14042000 Open source
20182018-12-31	Year over year	16.8%	Revenue: 21220000 Open source Revenue: 18167000 Open source
20192019-12-31	Year over year	38.4%	Revenue: 29373000 Open source Revenue: 21220000 Open source
20202020-12-31	Year over year	30.6%	Revenue: 38374000 Open source Revenue: 29373000 Open source
20212021-12-31	Year over year	15.5%	Revenue: 44310000 Open source Revenue: 38374000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -34.8% 2021

Net margin -37.4% 2021

Free cash flow margin -24.9% 2021

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Operating margin	-333.9%	Operating Income: -23838000 Open source Revenue: 7140000 Open source
20132013-12-31	Operating margin	-375.6%	Operating Income: -31719000 Open source Revenue: 8446000 Open source
20142014-12-31	Operating margin	-531.2%	Operating Income: -48533000 Open source Revenue: 9136000 Open source
20152015-12-31	Operating margin	-402.6%	Operating Income: -39457000 Open source Revenue: 9801000 Open source
20162016-12-31	Operating margin	-168.5%	Operating Income: -23660000 Open source Revenue: 14042000 Open source
20172017-12-31	Operating margin	-126.6%	Operating Income: -22995000 Open source Revenue: 18167000 Open source
20182018-12-31	Operating margin	-91.9%	Operating Income: -19504000 Open source Revenue: 21220000 Open source
20192019-12-31	Operating margin	-95.3%	Operating Income: -27985000 Open source Revenue: 29373000 Open source
20202020-12-31	Operating margin	-44.8%	Operating Income: -17195000 Open source Revenue: 38374000 Open source
20212021-12-31	Operating margin	-34.8%	Operating Income: -15404000 Open source Revenue: 44310000 Open source
20122012-12-31	Net margin	-543.3%	Net Income: -38794000 Open source Revenue: 7140000 Open source
20132013-12-31	Net margin	-369.9%	Net Income: -31242000 Open source Revenue: 8446000 Open source
20142014-12-31	Net margin	-565.4%	Net Income: -51659000 Open source Revenue: 9136000 Open source
20152015-12-31	Net margin	-446.2%	Net Income: -43728000 Open source Revenue: 9801000 Open source
20162016-12-31	Net margin	-221.3%	Net Income: -31071000 Open source Revenue: 14042000 Open source
20172017-12-31	Net margin	-170.2%	Net Income: -30925000 Open source Revenue: 18167000 Open source
20182018-12-31	Net margin	-95.3%	Net Income: -20213000 Open source Revenue: 21220000 Open source
20192019-12-31	Net margin	-126.6%	Net Income: -37175000 Open source Revenue: 29373000 Open source
20202020-12-31	Net margin	-52.6%	Net Income: -20168000 Open source Revenue: 38374000 Open source
20212021-12-31	Net margin	-37.4%	Net Income: -16554000 Open source Revenue: 44310000 Open source
20122012-12-31	Free cash flow margin	-352.7%	Revenue: 7140000 Open source Operating Cash Flow: -22425000 Open source Capital Expenditure: 2757000 Open source
20132013-12-31	Free cash flow margin	-450.3%	Revenue: 8446000 Open source Operating Cash Flow: -34064000 Open source Capital Expenditure: 3966000 Open source
20142014-12-31	Free cash flow margin	-535.7%	Revenue: 9136000 Open source Operating Cash Flow: -35935000 Open source Capital Expenditure: 13002000 Open source
20152015-12-31	Free cash flow margin	-386%	Revenue: 9801000 Open source Operating Cash Flow: -36174000 Open source Capital Expenditure: 1653000 Open source
20162016-12-31	Free cash flow margin	-174.6%	Revenue: 14042000 Open source Operating Cash Flow: -24307000 Open source Capital Expenditure: 209000 Open source
20172017-12-31	Free cash flow margin	-120.6%	Revenue: 18167000 Open source Operating Cash Flow: -21056000 Open source Capital Expenditure: 849000 Open source
20182018-12-31	Free cash flow margin	-94.3%	Revenue: 21220000 Open source Operating Cash Flow: -19425000 Open source Capital Expenditure: 580000 Open source
20192019-12-31	Free cash flow margin	-73.7%	Revenue: 29373000 Open source Operating Cash Flow: -21339000 Open source Capital Expenditure: 296000 Open source
20202020-12-31	Free cash flow margin	-43%	Revenue: 38374000 Open source Operating Cash Flow: -15959000 Open source Capital Expenditure: 559000 Open source
20212021-12-31	Free cash flow margin	-24.9%	Revenue: 44310000 Open source Operating Cash Flow: -9961000 Open source Capital Expenditure: 1093000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -10M 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Operating cash flow	-22425000	Operating Cash Flow: -22425000 Open source
20132013-12-31	Operating cash flow	-34064000	Operating Cash Flow: -34064000 Open source
20142014-12-31	Operating cash flow	-35935000	Operating Cash Flow: -35935000 Open source
20152015-12-31	Operating cash flow	-36174000	Operating Cash Flow: -36174000 Open source
20162016-12-31	Operating cash flow	-24307000	Operating Cash Flow: -24307000 Open source
20172017-12-31	Operating cash flow	-21056000	Operating Cash Flow: -21056000 Open source
20182018-12-31	Operating cash flow	-19425000	Operating Cash Flow: -19425000 Open source
20192019-12-31	Operating cash flow	-21339000	Operating Cash Flow: -21339000 Open source
20202020-12-31	Operating cash flow	-15959000	Operating Cash Flow: -15959000 Open source
20212021-12-31	Operating cash flow	-9961000	Operating Cash Flow: -9961000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -11.1M 2021

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20122012-12-31	Free cash flow	-25182000	Operating Cash Flow: -22425000 Open source Capital Expenditure: 2757000 Open source
20132013-12-31	Free cash flow	-38030000	Operating Cash Flow: -34064000 Open source Capital Expenditure: 3966000 Open source
20142014-12-31	Free cash flow	-48937000	Operating Cash Flow: -35935000 Open source Capital Expenditure: 13002000 Open source
20152015-12-31	Free cash flow	-37827000	Operating Cash Flow: -36174000 Open source Capital Expenditure: 1653000 Open source
20162016-12-31	Free cash flow	-24516000	Operating Cash Flow: -24307000 Open source Capital Expenditure: 209000 Open source
20172017-12-31	Free cash flow	-21905000	Operating Cash Flow: -21056000 Open source Capital Expenditure: 849000 Open source
20182018-12-31	Free cash flow	-20005000	Operating Cash Flow: -19425000 Open source Capital Expenditure: 580000 Open source
20192019-12-31	Free cash flow	-21635000	Operating Cash Flow: -21339000 Open source Capital Expenditure: 296000 Open source
20202020-12-31	Free cash flow	-16518000	Operating Cash Flow: -15959000 Open source Capital Expenditure: 559000 Open source
20212021-12-31	Free cash flow	-11054000	Operating Cash Flow: -9961000 Open source Capital Expenditure: 1093000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

65.9% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Liabilities / assets	202.5%	Total Liabilities: 68413000 Open source Total Assets: 33778000 Open source
20132013-12-31	Liabilities / assets	44.2%	Total Liabilities: 30887000 Open source Total Assets: 69918000 Open source
20142014-12-31	Liabilities / assets	56.9%	Total Liabilities: 43951000 Open source Total Assets: 77182000 Open source
20152015-12-31	Liabilities / assets	102.8%	Total Liabilities: 73223000 Open source Total Assets: 71201000 Open source
20162016-12-31	Liabilities / assets	165.6%	Total Liabilities: 76167000 Open source Total Assets: 45983000 Open source
20172017-12-31	Liabilities / assets	237.2%	Total Liabilities: 87564000 Open source Total Assets: 36913000 Open source
20182018-12-31	Liabilities / assets	72.2%	Total Liabilities: 33631000 Open source Total Assets: 46567000 Open source
20192019-12-31	Liabilities / assets	67.6%	Total Liabilities: 49159000 Open source Total Assets: 72717000 Open source
20202020-12-31	Liabilities / assets	61.3%	Total Liabilities: 49787000 Open source Total Assets: 81197000 Open source
20212021-12-31	Liabilities / assets	65.9%	Total Liabilities: 57403000 Open source Total Assets: 87056000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.94× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20122012-12-31	Current assets / current liabilities	0.71×	Current Assets: 27465000 Open source Current Liabilities: 38933000 Open source
20132013-12-31	Current assets / current liabilities	3.85×	Current Assets: 59751000 Open source Current Liabilities: 15530000 Open source
20142014-12-31	Current assets / current liabilities	1.75×	Current Assets: 54723000 Open source Current Liabilities: 31202000 Open source
20152015-12-31	Current assets / current liabilities	2.79×	Current Assets: 35912000 Open source Current Liabilities: 12849000 Open source
20162016-12-31	Current assets / current liabilities	1.76×	Current Assets: 26875000 Open source Current Liabilities: 15249000 Open source
20172017-12-31	Current assets / current liabilities	0.87×	Current Assets: 19118000 Open source Current Liabilities: 22002000 Open source
20182018-12-31	Current assets / current liabilities	2.66×	Current Assets: 30136000 Open source Current Liabilities: 11319000 Open source
20192019-12-31	Current assets / current liabilities	1.03×	Current Assets: 21716000 Open source Current Liabilities: 21085000 Open source
20202020-12-31	Current assets / current liabilities	1.41×	Current Assets: 34260000 Open source Current Liabilities: 24228000 Open source
20212021-12-31	Current assets / current liabilities	0.94×	Current Assets: 42678000 Open source Current Liabilities: 45188000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2012 2012-01-01 – 2012-12-31	−USD 38.79 million Exact value Exact value: -38794000 USD 2012-01-01 – 2012-12-31: -38794000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MARRONE BIO INNOVATIONS INC · 2012-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Net Income: -38794000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -38794000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000119312515372823/mbii-20141231.xml#4521567 Filing: 000119312515372823 The citation records this snapshot. The page link may show a newer release later.	−USD 22.43 million Exact value Exact value: -22425000 USD 2012-01-01 – 2012-12-31: -22425000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MARRONE BIO INNOVATIONS INC · 2012-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Operating Cash Flow: -22425000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -22425000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000119312515372823/mbii-20141231.xml#4518095 Filing: 000119312515372823 The citation records this snapshot. The page link may show a newer release later.	USD 2.76 million Exact value Exact value: 2757000 USD 2012-01-01 – 2012-12-31: 2757000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MARRONE BIO INNOVATIONS INC · 2012-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Capital Expenditure: 2757000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2757000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000119312515372823/mbii-20141231.xml#4521301 Filing: 000119312515372823 The citation records this snapshot. The page link may show a newer release later.	−USD 25.18 million Calculation and evidence -22425000 − 2757000 USD Exact free cash flow: -25182000 USD 2012-01-01 – 2012-12-31: -22425000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 2757000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MARRONE BIO INNOVATIONS INC · 2012-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Free cash flow: -25182000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -22425000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000119312515372823/mbii-20141231.xml#4518095 Filing: 000119312515372823 Input fundies:CapitalExpenditure: 2757000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000119312515372823/mbii-20141231.xml#4521301 Filing: 000119312515372823 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	−USD 31.24 million Exact value Exact value: -31242000 USD 2013-01-01 – 2013-12-31: -31242000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MARRONE BIO INNOVATIONS INC · 2013-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Net Income: -31242000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31242000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000119312516523740/mbii-20151231.xml#121526 Filing: 000119312516523740 The citation records this snapshot. The page link may show a newer release later.	−USD 34.06 million Exact value Exact value: -34064000 USD 2013-01-01 – 2013-12-31: -34064000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MARRONE BIO INNOVATIONS INC · 2013-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Operating Cash Flow: -34064000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -34064000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000119312516523740/mbii-20151231.xml#118304 Filing: 000119312516523740 The citation records this snapshot. The page link may show a newer release later.	USD 3.97 million Exact value Exact value: 3966000 USD 2013-01-01 – 2013-12-31: 3966000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MARRONE BIO INNOVATIONS INC · 2013-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Capital Expenditure: 3966000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3966000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000119312516523740/mbii-20151231.xml#121259 Filing: 000119312516523740 The citation records this snapshot. The page link may show a newer release later.	−USD 38.03 million Calculation and evidence -34064000 − 3966000 USD Exact free cash flow: -38030000 USD 2013-01-01 – 2013-12-31: -34064000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 3966000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MARRONE BIO INNOVATIONS INC · 2013-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Free cash flow: -38030000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -34064000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000119312516523740/mbii-20151231.xml#118304 Filing: 000119312516523740 Input fundies:CapitalExpenditure: 3966000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000119312516523740/mbii-20151231.xml#121259 Filing: 000119312516523740 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 51.66 million Exact value Exact value: -51659000 USD 2014-01-01 – 2014-12-31: -51659000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MARRONE BIO INNOVATIONS INC · 2014-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Net Income: -51659000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51659000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000156459017005870/mbii-20161231.xml#211265 Filing: 000156459017005870 The citation records this snapshot. The page link may show a newer release later.	−USD 35.94 million Exact value Exact value: -35935000 USD 2014-01-01 – 2014-12-31: -35935000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MARRONE BIO INNOVATIONS INC · 2014-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Operating Cash Flow: -35935000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -35935000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000156459017005870/mbii-20161231.xml#244563 Filing: 000156459017005870 The citation records this snapshot. The page link may show a newer release later.	USD 13 million Exact value Exact value: 13002000 USD 2014-01-01 – 2014-12-31: 13002000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MARRONE BIO INNOVATIONS INC · 2014-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Capital Expenditure: 13002000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 13002000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000156459017005870/mbii-20161231.xml#245234 Filing: 000156459017005870 The citation records this snapshot. The page link may show a newer release later.	−USD 48.94 million Calculation and evidence -35935000 − 13002000 USD Exact free cash flow: -48937000 USD 2014-01-01 – 2014-12-31: -35935000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 13002000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MARRONE BIO INNOVATIONS INC · 2014-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Free cash flow: -48937000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -35935000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000156459017005870/mbii-20161231.xml#244563 Filing: 000156459017005870 Input fundies:CapitalExpenditure: 13002000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000156459017005870/mbii-20161231.xml#245234 Filing: 000156459017005870 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 43.73 million Exact value Exact value: -43728000 USD 2015-01-01 – 2015-12-31: -43728000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MARRONE BIO INNOVATIONS INC · 2015-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Net Income: -43728000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -43728000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315218004788/mbii-20171231.xml#198568 Filing: 000149315218004788 The citation records this snapshot. The page link may show a newer release later.	−USD 36.17 million Exact value Exact value: -36174000 USD 2015-01-01 – 2015-12-31: -36174000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MARRONE BIO INNOVATIONS INC · 2015-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Operating Cash Flow: -36174000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -36174000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315218004788/mbii-20171231.xml#216720 Filing: 000149315218004788 The citation records this snapshot. The page link may show a newer release later.	USD 1.65 million Exact value Exact value: 1653000 USD 2015-01-01 – 2015-12-31: 1653000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MARRONE BIO INNOVATIONS INC · 2015-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Capital Expenditure: 1653000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1653000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315218004788/mbii-20171231.xml#216081 Filing: 000149315218004788 The citation records this snapshot. The page link may show a newer release later.	−USD 37.83 million Calculation and evidence -36174000 − 1653000 USD Exact free cash flow: -37827000 USD 2015-01-01 – 2015-12-31: -36174000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 1653000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MARRONE BIO INNOVATIONS INC · 2015-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Free cash flow: -37827000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -36174000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315218004788/mbii-20171231.xml#216720 Filing: 000149315218004788 Input fundies:CapitalExpenditure: 1653000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315218004788/mbii-20171231.xml#216081 Filing: 000149315218004788 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 31.07 million Exact value Exact value: -31071000 USD 2016-01-01 – 2016-12-31: -31071000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MARRONE BIO INNOVATIONS INC · 2016-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Net Income: -31071000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -31071000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315218004788/mbii-20171231.xml#198183 Filing: 000149315218004788 The citation records this snapshot. The page link may show a newer release later.	−USD 24.31 million Exact value Exact value: -24307000 USD 2016-01-01 – 2016-12-31: -24307000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MARRONE BIO INNOVATIONS INC · 2016-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Operating Cash Flow: -24307000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24307000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315218004788/mbii-20171231.xml#216493 Filing: 000149315218004788 The citation records this snapshot. The page link may show a newer release later.	USD 209,000 Exact value Exact value: 209000 USD 2016-01-01 – 2016-12-31: 209000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MARRONE BIO INNOVATIONS INC · 2016-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Capital Expenditure: 209000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 209000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315218004788/mbii-20171231.xml#215897 Filing: 000149315218004788 The citation records this snapshot. The page link may show a newer release later.	−USD 24.52 million Calculation and evidence -24307000 − 209000 USD Exact free cash flow: -24516000 USD 2016-01-01 – 2016-12-31: -24307000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 209000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MARRONE BIO INNOVATIONS INC · 2016-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Free cash flow: -24516000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24307000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315218004788/mbii-20171231.xml#216493 Filing: 000149315218004788 Input fundies:CapitalExpenditure: 209000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315218004788/mbii-20171231.xml#215897 Filing: 000149315218004788 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 30.93 million Exact value Exact value: -30925000 USD 2017-01-01 – 2017-12-31: -30925000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MARRONE BIO INNOVATIONS INC · 2017-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Net Income: -30925000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -30925000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315219004161/mbii-20181231.xml#205657 Filing: 000149315219004161 The citation records this snapshot. The page link may show a newer release later.	−USD 21.06 million Exact value Exact value: -21056000 USD 2017-01-01 – 2017-12-31: -21056000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MARRONE BIO INNOVATIONS INC · 2017-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Operating Cash Flow: -21056000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21056000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315219004161/mbii-20181231.xml#885576 Filing: 000149315219004161 The citation records this snapshot. The page link may show a newer release later.	USD 849,000 Exact value Exact value: 849000 USD 2017-01-01 – 2017-12-31: 849000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MARRONE BIO INNOVATIONS INC · 2017-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Capital Expenditure: 849000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 849000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315219004161/mbii-20181231.xml#890348 Filing: 000149315219004161 The citation records this snapshot. The page link may show a newer release later.	−USD 21.91 million Calculation and evidence -21056000 − 849000 USD Exact free cash flow: -21905000 USD 2017-01-01 – 2017-12-31: -21056000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 849000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MARRONE BIO INNOVATIONS INC · 2017-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Free cash flow: -21905000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21056000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315219004161/mbii-20181231.xml#885576 Filing: 000149315219004161 Input fundies:CapitalExpenditure: 849000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315219004161/mbii-20181231.xml#890348 Filing: 000149315219004161 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 20.21 million Exact value Exact value: -20213000 USD 2018-01-01 – 2018-12-31: -20213000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MARRONE BIO INNOVATIONS INC · 2018-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Net Income: -20213000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20213000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315220004083/mbii-20191231.xml#240868 Filing: 000149315220004083 The citation records this snapshot. The page link may show a newer release later.	−USD 19.43 million Exact value Exact value: -19425000 USD 2018-01-01 – 2018-12-31: -19425000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MARRONE BIO INNOVATIONS INC · 2018-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Operating Cash Flow: -19425000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -19425000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315220004083/mbii-20191231.xml#768409 Filing: 000149315220004083 The citation records this snapshot. The page link may show a newer release later.	USD 580,000 Exact value Exact value: 580000 USD 2018-01-01 – 2018-12-31: 580000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MARRONE BIO INNOVATIONS INC · 2018-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Capital Expenditure: 580000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 580000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315220004083/mbii-20191231.xml#772011 Filing: 000149315220004083 The citation records this snapshot. The page link may show a newer release later.	−USD 20.01 million Calculation and evidence -19425000 − 580000 USD Exact free cash flow: -20005000 USD 2018-01-01 – 2018-12-31: -19425000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 580000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MARRONE BIO INNOVATIONS INC · 2018-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Free cash flow: -20005000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -19425000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315220004083/mbii-20191231.xml#768409 Filing: 000149315220004083 Input fundies:CapitalExpenditure: 580000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315220004083/mbii-20191231.xml#772011 Filing: 000149315220004083 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−USD 37.18 million Exact value Exact value: -37175000 USD 2019-01-01 – 2019-12-31: -37175000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MARRONE BIO INNOVATIONS INC · 2019-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Net Income: -37175000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -37175000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315221006648/mbii-20201231.xml#295575 Filing: 000149315221006648 The citation records this snapshot. The page link may show a newer release later.	−USD 21.34 million Exact value Exact value: -21339000 USD 2019-01-01 – 2019-12-31: -21339000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MARRONE BIO INNOVATIONS INC · 2019-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Operating Cash Flow: -21339000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -21339000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315221006648/mbii-20201231.xml#301942 Filing: 000149315221006648 The citation records this snapshot. The page link may show a newer release later.	USD 296,000 Exact value Exact value: 296000 USD 2019-01-01 – 2019-12-31: 296000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MARRONE BIO INNOVATIONS INC · 2019-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Capital Expenditure: 296000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 296000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315221006648/mbii-20201231.xml#303639 Filing: 000149315221006648 The citation records this snapshot. The page link may show a newer release later.	−USD 21.64 million Calculation and evidence -21339000 − 296000 USD Exact free cash flow: -21635000 USD 2019-01-01 – 2019-12-31: -21339000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 296000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MARRONE BIO INNOVATIONS INC · 2019-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Free cash flow: -21635000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -21339000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315221006648/mbii-20201231.xml#301942 Filing: 000149315221006648 Input fundies:CapitalExpenditure: 296000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315221006648/mbii-20201231.xml#303639 Filing: 000149315221006648 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 20.17 million Exact value Exact value: -20168000 USD 2020-01-01 – 2020-12-31: -20168000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MARRONE BIO INNOVATIONS INC · 2020-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Net Income: -20168000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -20168000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#585202 Filing: 000149315222012535 The citation records this snapshot. The page link may show a newer release later.	−USD 15.96 million Exact value Exact value: -15959000 USD 2020-01-01 – 2020-12-31: -15959000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MARRONE BIO INNOVATIONS INC · 2020-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Operating Cash Flow: -15959000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -15959000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#623805 Filing: 000149315222012535 The citation records this snapshot. The page link may show a newer release later.	USD 559,000 Exact value Exact value: 559000 USD 2020-01-01 – 2020-12-31: 559000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MARRONE BIO INNOVATIONS INC · 2020-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Capital Expenditure: 559000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 559000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#629784 Filing: 000149315222012535 The citation records this snapshot. The page link may show a newer release later.	−USD 16.52 million Calculation and evidence -15959000 − 559000 USD Exact free cash flow: -16518000 USD 2020-01-01 – 2020-12-31: -15959000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 559000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MARRONE BIO INNOVATIONS INC · 2020-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Free cash flow: -16518000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -15959000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#623805 Filing: 000149315222012535 Input fundies:CapitalExpenditure: 559000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#629784 Filing: 000149315222012535 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 16.55 million Exact value Exact value: -16554000 USD 2021-01-01 – 2021-12-31: -16554000 USD Inspect Net Income Open source Share or cite Citation for Net Income · MARRONE BIO INNOVATIONS INC · 2021-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Net Income: -16554000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16554000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#584350 Filing: 000149315222012535 The citation records this snapshot. The page link may show a newer release later.	−USD 9.96 million Exact value Exact value: -9961000 USD 2021-01-01 – 2021-12-31: -9961000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · MARRONE BIO INNOVATIONS INC · 2021-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Operating Cash Flow: -9961000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9961000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#622851 Filing: 000149315222012535 The citation records this snapshot. The page link may show a newer release later.	USD 1.09 million Exact value Exact value: 1093000 USD 2021-01-01 – 2021-12-31: 1093000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · MARRONE BIO INNOVATIONS INC · 2021-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Capital Expenditure: 1093000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1093000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#628953 Filing: 000149315222012535 The citation records this snapshot. The page link may show a newer release later.	−USD 11.05 million Calculation and evidence -9961000 − 1093000 USD Exact free cash flow: -11054000 USD 2021-01-01 – 2021-12-31: -9961000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1093000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · MARRONE BIO INNOVATIONS INC · 2021-12-31 MARRONE BIO INNOVATIONS INC (edgar:1441693) Free cash flow: -11054000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T07:42:06Z Snapshot: 7e93a8b381c5faff50a2f1ba4be7d7f1aef053f38a675fb65465d7ff1cea2778 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1441693?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9961000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#622851 Filing: 000149315222012535 Input fundies:CapitalExpenditure: 1093000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1441693/000149315222012535/form10-ka.htm#628953 Filing: 000149315222012535 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

138 filings · 3,012 latest values · 3,012 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001441693, 1441693, MBII, edgar:1441693

Also known as MARRONE BIO INNOVATIONS INC, MARRONE ORGANICS INNOVATIONS INC, Marrone Bio Innovations, Inc., Pro Farm Group, Inc.

MARRONE BIO INNOVATIONS INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation